Viewing Study NCT02629692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:57 PM
Ignite Modification Date: 2026-02-24 @ 3:52 AM
Study NCT ID: NCT02629692
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-07-31
First Post: 2015-12-10
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sponsor: Sun Pharma Advanced Research Company Limited
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthy (For Part A) View
None Chronic Myeloid Leukemia (for Part B and C) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CML View
None Chronic Myelogenous Leukemia View
None K0706 View
None Vodobatinib View
None ponatinib-refractory/intolerant View
None treatment refractory chronic myeloid leukemia View
None Ponatinib View